Table 1.

Baseline demographics and disease characteristics

Cohort 1 (N = 6)Cohort 2 (N = 6)Cohort 3 (N = 6)TotalP
Age, year0.150
 Median60576360
 Range57–6651–6353–6851–68
Weight, lbs0.103
 Median196.2228.4188.4202.3
 Range159.7–224.3178.5–269.9151.2–227.3151.2–269.9
Race, N (%)1.000
 Caucasian6 (100.0)6 (100.0)6 (100.0)18 (100.0)
ECOG1.000
 PS = 06 (100.0)6 (100.0)6 (100.0)18 (100.0)
Gleason sum, N (%)0.023
 ≤62 (33.3)1 (16.7)4 (66.7)7 (38.9)
 74 (66.7)5 (83.3)0 (0.0)9 (50.0)
 ≥80 (0.0)0 (0.0)2 (33.3)2 (11.1)
Clinical stage, N (%)0.100
 T1c2 (33.3)5 (83.3)2 (33.3)9 (50.0)
 T2a4 (66.7)0 (0.0)3 (50.0)7 (38.9)
 T3a0 (0.0)1 (16.7)1 (16.7)2 (11.1)
PSA, ng/mL0.466
 Median5.75.94.25.0
 Range3.0–9.13.6–13.23.2–8.93.0–13.2
LDH, U/L0.927
 Median151139151150
 Range128–170129–23795–19995–237
Hemoglobin, g/dL0.654
 Median15.115.415.115.2
 Range14.3–15.514.7–16.912.6–15.912.6–16.9
Alkaline phosphatase, U/L0.548
 Median68657572
 Range46–11247–8850–9746–112
NCCN risk group, N (%)0.007
 Low2 (33.3)1 (16.7)4 (66.7)7 (38.9)
 Intermediate4 (66.7)4 (66.7)0 (0.0)8 (44.4)
 High0 (0.0)1 (16.7)2 (33.3)3 (16.7)
  • Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.